Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Perfuze

Financiado

Cerrado

A simple repeatable way to completely remove a clot from the brain in one pass

Stroke is the third most common cause of death globally and is the leading cause of adult physical disability. Globally, seventeen million people had a stroke in 20152. Of these, 33% died and 33% were permanently disabled. A strok... ver más

31/07/2021

Perfuze Limited

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

PERFUZE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 4 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-07-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 56% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

4 Participantes

Perfuze Limited

2.48M€ | Lider

ERICSSON ESPANA

469.94K€ | Participante

VOZTELECOM OIGAA360

470.78K€ | Participante

XFERA MOVILES

490.36K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

Predistroke Portable solution for prehospital diagnosis of stroke in th... 71K€ Cerrado

StrokeAlert- WomenEU Striking Stroke- enhancing and expanding StrokeAlert’s busin... 75K€ Cerrado

LVOCheck Diagnosis of large vessel occlusion (LVO) in acute stroke fo... 4M€ Cerrado

TED2021-131742B-I00 DESARROLLO DE UNA HERRAMIENTA BIO-DIGITAL PARA OPTIMIZAR EL... 107K€ Cerrado

NIMBLE WOMENTECHEU A novel non-invasive and non-ionizing medical device for mon... 75K€ Cerrado

NIMBLE System "The NIMBLE System: A novel non-invasive and non-ionizing me... 3M€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2019-07-31
Fecha Fin: 2021-07-31

Líder del proyecto

PERFUZE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Stroke is the third most common cause of death globally and is the leading cause of adult physical disability. Globally, seventeen million people had a stroke in 20152. Of these, 33% died and 33% were permanently disabled. A stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow, and causing brain damage. Stroke is a devastating disease. Perfuze has developed aspiration catheter technology intended to ingest the clot in a single attempt. No accessory devices or sophisticated techniques are required, meaning the procedure can be performed by a single operator. This maximises the chance of complete clot ingestion within the occluded vessel, complete flow restoration and improved patient outcomes. Multiple iterations have been required to reach the existing Millipede design. Pilot manufacturing lines utilising customised coiling and wire forming equipment have been built. Component and assembly drawings and specifications have been defined. Six preclinical animal studies have been performed to compliment proof-of-concept bench testing. The potential market opportunity is huge. In the US and EU alone, it is valued at $2.5bn in 2018. The Perfuze platform is uniquely positioned to exploit the recent, dramatic clinical shift away from medical therapy to endovascular device treatment of ischemic stroke. This SME Instrument Phase 2 will enable company scale up and creation of 52 jobs by 2024 and will generate over €17m in turnover.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores